SONO TEK CORP
For the period ended Feb 29, 2024. Filed May 23, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed May 23, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
| ITEM 16 | 10-K SUMMARY |
|---|
None.
FORM 10-K
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND NOTES
FOR THE YEARS ENDED FEBRUARY 29, 2024 and February 28, 2023
Marcum LLP (PCAOB ID No:688)
Consolidated Statements of Stockholders' Equity
Notes to Consolidated Financial Statements
To the Shareholders and Board of Directors of
Sono-Tek Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Sono-Tek Corporation (the “Company”) as of February 29, 2024 and February 28, 2023, the related consolidated statements of income, stockholders’ equity and cash flows for each of the two years in the period ended February 29, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of February 29, 2024 and February 28, 2023, and the results of its operations and its cash flows for each of the two years in the period ended February 29, 2024, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.
/s/ Marcum LLP
Marcum LLP
We have served as the Company’s auditor since 2020.
East Hanover, NJ
May 23, 2024
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $2,134,786 | $3,354,601 |
| Marketable securities | 9,711,351 | 8,090,000 |
| Accounts receivable (less allowance of $12,225) | 1,470,711 | 1,633,866 |
| Inventories | 5,221,980 | 3,242,909 |
| Prepaid expenses and other current assets | 207,738 | 254,046 |
| Total current assets | 18,746,566 | 16,575,422 |
| Land | 250,000 | 250,000 |
| Buildings, equipment, furnishings and leasehold improvements, net | 2,832,156 | 2,624,996 |
| Intangible assets, net | 47,566 | 57,202 |
| Deferred tax asset | 1,255,977 | 667,098 |
| TOTAL ASSETS | $23,132,265 | $20,174,718 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $1,049,742 | $810,863 |
| Accrued expenses | 1,739,478 | 1,427,446 |
| Customer deposits | 3,419,706 | 2,838,165 |
| Income taxes payable | 414,807 | 381,421 |
| Total current liabilities | 6,623,733 | 5,457,895 |
| Deferred tax liability | 229,534 | 82,865 |
| Total Liabilities | 6,853,267 | 5,540,760 |
| Commitments and Contingencies (Note 12) | ||
| Stockholders’ Equity | ||
| Common stock, $.01 par value; 25,000,000 shares authorized, 15,750,880 and 15,742,073 issued and outstanding as of February 29, 2024, and February 28, 2023, respectively | 157,509 | 157,421 |
| Additional paid-in capital | 9,770,387 | 9,566,898 |
| Accumulated earnings | 6,351,102 | 4,909,639 |
| Total stockholders’ equity | 16,278,998 | 14,633,958 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $23,132,265 | $20,174,718 |
| Fiscal Year Ended | ||
|---|---|---|
| February 29, 2024 | February 28, 2023 | |
| Net Sales | $19,699,886 | $15,058,203 |
| Cost of Goods Sold | 9,855,311 | 7,406,196 |
| Gross Profit | 9,844,575 | 7,652,007 |
| Operating Expenses | ||
| Research and product development | 2,885,773 | 2,149,525 |
| Marketing and selling | 3,695,870 | 3,169,730 |
| General and administrative | 2,080,447 | 1,649,761 |
| Total Operating Expenses | 8,662,090 | 6,969,016 |
| Operating Income | 1,182,485 | 682,991 |
| Other Income (Expense): | ||
| Interest and Dividend Income | 529,735 | 140,042 |
| Net unrealized gain/(loss) on marketable securities | 32,360 | (33,119) |
| Income before Income Taxes | 1,744,580 | 789,914 |
| Income Tax Expense | 303,117 | 154,009 |
| Net Income | $1,441,463 | $635,905 |
| Basic Earnings Per Share | $0.09 | $0.04 |
| Diluted Earnings Per Share | $0.09 | $0.04 |
| Weighted Average Shares – Basic | 15,743,763 | 15,735,451 |
| Weighted Average Shares – Diluted | 15,774,007 | 15,769,499 |
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
YEARS ENDED FEBRUARY 29, 2024 AND FEBRUARY 28, 2023
| Shares | Amount | Additional Paid – In Capital | Accumulated Earnings | Total Stockholders’ Equity | |
|---|---|---|---|---|---|
| Balance - February 28, 2022 | 15,729,175 | $157,292 | $9,310,287 | $4,273,734 | $13,741,313 |
| Stock based compensation expense | 256,740 | 256,740 | |||
| Cashless exercise of stock options | 12,898 | 129 | (129) | — | |
| Net Income | 635,905 | 635,905 | |||
| Balance - February 28, 2023 | 15,742,073 | $157,421 | $9,566,898 | $4,909,639 | $14,633,958 |
| Stock based compensation expense | 203,577 | 203,577 | |||
| Cashless exercise of stock options | 8,807 | 88 | (88) | — | |
| Net Income | 1,441,463 | 1,441,463 | |||
| Balance - February 29, 2024 | 15,750,880 | $157,509 | $9,770,387 | $6,351,102 | $16,278,998 |
| Fiscal Year Ended | ||
|---|---|---|
| February 29, 2024 | February 28, 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net Income | $1,441,463 | $635,905 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 597,166 | 510,868 |
| Stock based compensation expense | 203,577 | 256,740 |
| Accounts receivable reserve | — | (43,898) |
| Inventory reserve | 47,875 | 4,864 |
| Unrealized (gain) loss on marketable securities | (32,360) | 33,119 |
| Deferred tax asset, net | (442,210) | (512,337) |
| (Increase) Decrease in: | ||
| Accounts receivable | 163,155 | (497,463) |
| Inventories | (2,026,946) | (874,531) |
| Prepaid expenses and other assets | 46,308 | 69,258 |
| (Decrease) Increase in: | ||
| Accounts payable | 238,879 | 126,352 |
| Accrued expenses | 312,032 | (376,582) |
| Customer deposits | 581,541 | 1,670,197 |
| Income taxes payable | 33,386 | 322,547 |
| Net Cash Provided by Operating Activities | 1,163,866 | 1,325,039 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of equipment, furnishings and leasehold improvements | (794,690) | (555,867) |
| Sale of marketable securities | 20,237,051 | 14,329,159 |
| Purchase of marketable securities | (21,826,042) | (16,584,288) |
| Net Cash Used In Investing Activities | (2,383,681) | (2,810,996) |
| NET (DECREASE) IN CASH AND CASH EQUIVALENTS | (1,219,815) | (1,485,957) |
| CASH AND CASH EQUIVALENTS: | ||
| Beginning of year | 3,354,601 | 4,840,558 |
| End of year | $2,134,786 | $3,354,601 |
| Supplemental Cash Flow Disclosure: | ||
| Interest Paid | $— | $— |
| Income Taxes Paid | $712,092 | $363,590 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED FEBRUARY 29, 2024 AND FEBRUARY 28, 2023
NOTE 1: BUSINESS DESCRIPTION
Sono-Tek Corporation (the “Company”, “Sono-Tek”, “We” or “Our”) was incorporated in New York on March 21, 1975. We are the world leader in the design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. We design and manufacture custom-engineered ultrasonic coating systems incorporating our patented technology, in combination with strong applications engineering knowledge, to assist our customers in achieving their desired coating solutions.
NOTE 2: SIGNIFICANT ACCOUNTING POLICIES
Advertising Expenses* -*The Company expenses the cost of advertising in the period in which the advertising takes place. Advertising expense for fiscal 2024 and fiscal 2023 was $371,000 and $297,500, respectively.
***Accounts Receivable, net -***In the normal course of business, the Company extends credit to customers. Accounts receivable, less an allowance for credit losses, reflect the net realizable value of receivables and approximate fair value. The Company records a bad debt expense/allowance based on management’s estimate of uncollectible accounts. All outstanding accounts receivable accounts are reviewed for collectability on an individual basis.
Cash and Cash Equivalents* -*Cash and cash equivalents consist of money market mutual funds, short term commercial paper and short-term certificates of deposit with original maturities of 90 days or less. At February 29, 2024, the Company had $1,819,000 of cash in excess of the FDIC insured limit.
Consolidation - The accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiary, Sono-Tek Industrial Park, LLC (“SIP”) in conformity with generally accepted accounting principles in the United States (“GAAP”). SIP operates as a real estate holding company for the Company’s real estate operations. All intercompany accounts and transactions have been eliminated in consolidation.
Earnings Per Share* -*Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock under the treasury stock method.
Equipment, Furnishings and Leasehold Improvements - Equipment, furnishings and leasehold improvements are stated at cost. Depreciation of equipment and furnishings is computed by use of the straight-line method based on the estimated useful lives of the assets, which range from three to five years.
Fair Value of Financial Instruments - The Company applies Accounting Standards Codification (“ASC”) 820,Fair Value Measurement(“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.
The carrying amounts of financial instruments reported in the accompanying consolidated financial statements for current assets and current liabilities approximate the fair value because of the immediate or short-term maturities of the financial instruments.
The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:
Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.
Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.
The fair values of financial assets of the Company were determined using the following categories at February 29, 2024 and February 28, 2023, respectively:
| Level 1 · Level 2 · Level 3 · Total | ||||
|---|---|---|---|---|
| Marketable Securities – February 29, 2024 | $9,711,351 | $— | $— | $9,711,351 |
| Marketable Securities – February 28, 2023 | $7,361,000 | $729,000 | $— | $8,090,000 |
Marketable Securities include certificates of deposit and US Treasury securities, totaling $9,711,351 and $8,090,000 that are considered to be highly liquid and easily tradeable as of February 29, 2024 and February 28, 2023, respectively. US Treasury securities are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 and certificates of deposit are classified as Level 2 within the Company’s fair value hierarchy. The Company’s marketable securities are considered to be trading securities as defined under ASC 320 “Investments – Debt and Equity Securities.”
Income Taxes - The Company accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences of "temporary differences" by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized. The Company uses a recognition threshold and a measurement attribute for financial statement recognition and measurement of tax positions taken or expected to be taken in a return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. As of February 29, 2024 and February 28, 2023, there wereno uncertain tax positions.
Intangible Assets* -*Include costs of patent applications which are deferred and charged to operations over seventeen 17 years for domestic patents and twelve 12 years for foreign patents, which is considered the useful life. Amortization expense for the years ended February 29, 2024 and February 28, 2023 was $16,434 and $18,814, respectively. The accumulated amortization of patents is $212,861 and $202,681 at February 29, 2024 and February 28, 2023, respectively. Annual amortization expense of such intangible assets is expected to be approximately $16,000 per year for the next five years.
Inventories* -*Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out (FIFO) method for raw materials, subassemblies and work-in-progress and the specific identification method for finished goods. Management compares the cost of inventory with the net realizable value and, if applicable, an allowance is made for writing down the inventory to its net realizable value, if lower than cost. On an ongoing basis, inventory is reviewed for potential write-down for estimated obsolescence or unmarketable inventory based upon forecasts for future demand and market conditions.
***Land and Buildings -***Land and buildings are stated at cost. Buildings are being depreciated by use of the straight-line method based on an estimated useful life of forty years.
At February 29, 2024 and February 28, 2023, the Company had Land, stated at cost of $250,000.
Long-Lived Assets* -*The Company periodically evaluates the carrying value of long-lived assets, including intangible assets, when events and circumstances warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated undiscounted cash flow from such asset is separately identifiable and is less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair market value of the long-lived asset. Fair market value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. No impairment losses were identified or recorded for the years ended February 29, 2024 and February 28, 2023 on the Company’s long-lived assets.
Management Estimates* -*The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
***New Accounting Pronouncements ***– In June 2016, the FASB issued ASU 2016-13 - Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments. Codification Improvements to Topic 326, Financial Instruments – Credit Losses, have been released in November 2018 (2018-19), November 2019 (2019-10 and 2019-11) and a January 2020 Update (2020-02) that provided additional guidance on this Topic. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For SEC filers meeting certain criteria, the amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For SEC filers that meet the criteria of a smaller reporting company (including this Company) and for non-SEC registrant public companies and other organizations, the amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early adoption will be permitted for all organizations for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company has adopted ASU 2016-13 as updated and the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted - In December 2023, the FASB issued ASU 2023-09,*Improvements to Income Tax Disclosures.*This ASU requires greater disaggregation of information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.
In November 2023, the FASB issued ASU 2023-07,Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating officer decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. The ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing segment disclosures in Topic 280. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures, and does not expect the standard will have a material impact on the Company’s consolidated financial statements and related disclosures.
Product Warranty - Expected future product warranty expense is recorded when revenue is recognized for product sales.
Research and Product Development Expenses* -*Research and product development expenses represent engineering and other expenditures incurred for developing new products, for refining the Company's existing products and for developing systems to meet unique customer specifications for potential orders or for new industry applications and are expensed as incurred.
During fiscal 2024 and fiscal 2023, the Company spent approximately $2,886,000 and $2,149,000, respectively, on research and development activities related to new products and services and the ongoing improvement of existing products and services.
Revenue Recognition - The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps:
| · | Identification of the contract, or contracts, with a customer |
| · | Identification of the performance obligations in the contract |
| · | Determination of the transaction price |
| · | Allocation of the transaction price to the performance obligations in the contract |
| · | Recognition of revenue when, or as, performance obligations are satisfied |
Stock-Based Compensation - The Company currently uses a Black-Scholes option pricing model to calculate the fair value of its stock options. The fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk free interest rate; volatility; and expected lives of the awards. The Company primarily uses historical data to determine the assumptions to be used in the Black-Scholes model. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment.
ASC 718 requires the recognition of the fair value of stock compensation expense to be recognized over the vesting term of such award. The Company accounts for forfeitures as they occur.
NOTE 3: REVENUE RECOGNITION
The Company’s sales revenue is derived primarily from short term contracts with customers, which, on average, are in effect for less than twelve months. Sales revenue from manufactured equipment transferred at a single point in time accounts for a majority of the Company’s revenue.
Sales revenue is recognized when control of the Company’s manufactured equipment is transferred to its customers in an amount that reflects the consideration the Company expects to receive based upon the agreed transaction price. The Company’s performance obligations are satisfied when its customers take control of the purchased equipment, in accordance with the contract terms. Based on prior experience, the Company reasonably estimates its sales returns and warranty reserves. Sales are presented net of discounts and allowances. Discounts and allowances are determined when a transaction is negotiated. The Company does not grant its customers or independent representatives the ability to return equipment nor does it grant price adjustments after a sale is complete.
The Company does not capitalize any sales commission costs related to the acquisition of a contract. All commissions related to a performance obligation that are satisfied at a point in time are expensed when the customer takes control of the purchased equipment and revenue is recognized.
The Company applies the practical expedient in paragraph ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one-year or less.
At February 29, 2024, the Company had received $3,420,000 in cash deposits, representing contract liabilities, and had issued Letters of Credit in the amount of $72,000 to secure these cash deposits. At February 29, 2024, the Company was utilizing $72,000 of its available credit line to collateralize these letters of credit.
At February 28, 2023, the Company had received $2,838,000 in cash deposits, representing contract liabilities, and had issued Letters of Credit in the amount of $145,000 to secure these cash deposits. At February 28, 2023, the Company was utilizing $145,000 of its available credit line to collateralize these letters of credit.
The Company’s sales revenue, by product line is as follows:
| Twelve Months Ended | ||||
|---|---|---|---|---|
| February 29, · February 28, | ||||
| 2024 | % of total | 2023 | % of total | |
| Fluxing Systems | $724,000 | 4% | $1,179,000 | 8% |
| Integrated Coating Systems | 2,889,000 | 14% | 1,114,000 | 7% |
| Multi-Axis Coating Systems | 10,075,000 | 51% | 6,785,000 | 45% |
| OEM Systems | 1,533,000 | 8% | 2,144,000 | 14% |
| Other | 4,479,000 | 23% | 3,836,000 | 26% |
| TOTAL | $19,700,000 | $15,058,000 | ||
NOTE 4: STOCK-BASED COMPENSATION
Stock Options – In May 2023, the Company’s Board of Directors authorized the creation of the 2023 Stock Incentive Plan (the “2023 Plan”) pursuant to which the Company may grant up to 2,500,000 options or shares to officers, directors, employees and consultants of the Company and its subsidiaries. The Company’s shareholders approved the adoption of the 2023 Plan in August 2023. The 2023 Plan replaced the 2013 Stock Incentive Plan (the “2013 Plan”) under which no additional options or shares could be granted after June 2023. There are currently 65,793 and 229,749 options outstanding, respectively, under the 2023 Plan and the 2013 Plan.
Under the 2023 Stock Incentive Plan, as amended (the "2023 Plan"), options can be granted to officers, directors, consultants and employees of the Company and its subsidiaries to purchase up to 2,500,000 shares of the Company's common stock. Under the 2023 Plan options expire ten years after the date of grant.
During fiscal 2024, the Company granted options to acquire 54,813 shares to employees exercisable at prices ranging from $4.79 to $5.60 and options to acquire 18,380 shares to the non-employee members of the board of directors with an exercise price of $4.79. The options granted to employees and directors vest over three years and expire in ten years. The options granted by the Company during fiscal 2024 had a combined weighted average grant date fair value of $3.11 per share.
During fiscal 2023, the Company granted options to acquire 28,239 shares to employees exercisable at prices ranging from $5.45 to $5.96 and options to acquire 16,500 shares to the non-employee members of the board of directors with an exercise price of $5.50. The options granted to employees and directors vest over three years and expire in ten years. The options granted by the Company during fiscal 2023 had a combined weighted average grant date fair value of $3.44 per share.
A summary of the activity for both plans, for fiscal 2024 and fiscal 2023 is as follows:
| Weighted Average | |||||
|---|---|---|---|---|---|
| Stock Options · Exercise Price $ · Remaining | |||||
| Outstanding · Exercisable · Outstanding · Exercisable · Term - Years | |||||
| Balance - February 28, 2022 | 253,710 | 61,690 | $4.46 | $3.53 | 8.94 |
| Granted | 44,739 | 5.71 | |||
| Exercised | (16,973) | (1.77) | |||
| Cancelled | (30,717) | (4.66) | |||
| Balance - February 28, 2023 | 250,759 | 133,609 | $4.84 | $4.62 | 8.52 |
| Granted | 73,193 | $5.02 | |||
| Exercised | (19,701) | (3.62) | |||
| Cancelled | (8,709) | (4.20) | |||
| Balance - February 29, 2024 | 295,542 | 181,376 | $4.99 | $4.89 | 8.04 |
The aggregate intrinsic value of the Company’s vested and exercisable options at February 29, 2024 was $167,709.
For the years ended February 29, 2024 and February 28, 2023 the Company recognized $203,577 and $256,740 in stock based compensation expense, respectively. Such amounts are included in general and administrative expenses on the consolidated statements of income. Total compensation expense related to non-vested options not yet recognized as of February 29, 2024 was $298,000 and will be recognized over the next three years based on vesting date. The amount of future stock option compensation expense could be affected by any future option grants or by any forfeitures. During the year ended February 29, 2024, the Company had net settlement exercises of stock options, whereby, the optionee did not pay cash for the options but instead received the number of shares equal to the difference between the exercise price and the market price on the date of exercise. Net settlement exercises during the year ended February 29, 2024 resulted in 8,807 shares of common stock issued.
Determining the appropriate fair value of the stock-based awards requires the input of subjective assumptions, including the fair value of the Company’s common stock, and for stock options, the expected life of the option, and the expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
The expected term of the options is estimated based on the Company’s historical exercise rate. The expected life of awards that vest immediately use the contractual maturity since they are vested when issued. For stock price volatility, the Company uses its expected volatility of the price of the Company’s common stock based on historical activity. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option at the grant-date.
The weighted-average fair value of options has been estimated on the date of grant using the Black-Scholes options-pricing model. The weighted-average Black-Scholes assumptions are as follows:
| Fiscal Year Ended | ||
|---|---|---|
| February 29, 2024 | February 28, 2023 | |
| Expected life | 5 - 8 years | 5 - 8 years |
| Risk free interest rate | 2.82% - 4.39% | 2.82% – 4.02% |
| Expected volatility | 55.02% - 62.48% | 55.02% - 62.01% |
| Expected dividend yield | 0% | 0% |
NOTE 5: INVENTORIES
Inventories consist of the following:
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| Raw materials and subassemblies | $2,270,567 | $1,868,689 |
| Finished goods | 1,785,952 | 613,915 |
| Work in process | 1,165,461 | 760,305 |
| Total | $5,221,980 | $3,242,909 |
The Company maintains an allowance for slow-moving inventory for raw materials and finished goods. The recorded allowances at February 29, 2024 and February 28, 2023, totaled $380,400 and $332,525, respectively.
NOTE 6: BUILDINGS, EQUIPMENT, FURNISHINGS AND LEASEHOLD IMPROVEMENTS
Buildings, equipment, furnishings and leasehold improvements consist of the following:
| February 29, | February 28, | |
|---|---|---|
| 2024 | 2023 | |
| Buildings | $2,250,000 | $2,250,000 |
| Laboratory equipment | 1,733,911 | 1,647,951 |
| Machinery and equipment | 1,891,345 | 1,807,817 |
| Leasehold improvements | 924,356 | 789,044 |
| Tradeshow and demonstration equipment | 1,151,899 | 1,137,346 |
| Furniture and fixtures | 1,771,084 | 1,302,545 |
| Totals | 9,722,595 | 8,934,703 |
| Less: Accumulated depreciation | (6,890,439) | (6,309,707) |
| $2,832,156 | $2,624,996 |
Depreciation expense for the years ended February 29, 2024 and February 28, 2023 was $580,732 and $492,055, respectively.
NOTE 7: ACCRUED EXPENSES
Accrued expenses consist of the following:
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| Accrued compensation | $579,757 | $352,619 |
| Estimated warranty costs | 524,875 | 500,650 |
| Accrued sales tax | 152,547 | — |
| Accrued commissions | 133,771 | 157,927 |
| Professional fees | 74,826 | 100,921 |
| Other accrued expenses | 273,702 | 315,329 |
| Total accrued expenses | $1,739,478 | $1,427,446 |
NOTE 8: REVOLVING LINE OF CREDIT
The Company has a $1,500,000 revolving line of credit at prime which was 8.50% at February 29, 2024 and 7.75% at February 28, 2023. The revolving credit line is collateralized by the Company’s accounts receivable and inventory. The revolving credit line is payable on demand and must be retired for a 30-day period, once annually. If the Company fails to perform the 30-day annual pay down or if the bank elects to terminate the credit line, the bank may, at its option, convert the outstanding balance to a 36-month term note with payments including interest in 36 equal installments.
As of February 29, 2024, $72,000 of the Company’s credit line was being utilized to collateralize Letters of Credit issued to customers that have remitted cash deposits to the Company on existing orders. The Letters of Credit expire in April 2024. As of February 29, 2024, there were no outstanding borrowings under the line of credit and the unused portion of the credit line was $1,428,000.
As of February 28, 2023, $145,000 of the Company’s credit line was being utilized to collateralize Letters of Credit issued to customers that have remitted cash deposits to the Company on existing orders. The Letters of Credit expired in May and July 2023. As of February 28, 2023, there were no outstanding borrowings under the line of credit and the unused portion of the credit line was $1,355,000.
NOTE 9: INCOME TAXES
The annual provision (benefit) for income taxes differs from amounts computed by applying the maximum U.S. Federal income tax rate of 21% to pre-tax income as follows:
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| Expected federal income tax | $366,362 | $165,882 |
| State tax, net of federal | 52,510 | 37,204 |
| Research and development tax credits | (161,525) | (127,329) |
| Permanent differences | 45,770 | 78,252 |
| Income tax expense | $303,117 | $154,009 |
Components of the current and deferred tax expense are as follows:
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| Current: | ||
| Federal | $716,003 | $438,263 |
| State | 123,743 | 83,525 |
| Total current income tax | 839,746 | 521,788 |
| Deferred: | ||
| Federal | (471,396) | (321,458) |
| State | (65,233) | (46,321) |
| Total deferred income tax | (536,629) | (367,779) |
| Income tax expense | $303,117 | $154,009 |
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and projections for future taxable income over periods in which the deferred tax assets are deductible. Management believes it is more likely than not that the Company will realize the benefits of these deductible differences.
The incorporation of the new tax laws for 2023, requires the Company to capitalize for income tax purposes research and development expenses incurred during the year and for such expenses to be amortized over a five year period. As a result, a deferred tax asset “Capitalized R&D expenses – IRC Section 174” has been recorded.
The Company does not have any uncertain tax positions in 2024. There are no interest and penalties related to uncertain tax positions in 2024. As of February 29, 2024, open years related to the federal and state jurisdictions are 2023, 2022 and 2021.
The deferred tax asset and liability are comprised of the following:
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| Deferred tax asset | ||
| Allowance for inventory | $91,000 | $76,000 |
| Allowance for accounts receivable | 3,000 | 3,000 |
| Capitalized R&D expenses – IRC Section 174 | 985,000 | 441,000 |
| Accrued expenses and other | 177,000 | 147,000 |
| Deferred tax asset – Long Term | $1,256,000 | $667,000 |
| Deferred tax liability | ||
| Building and leasehold depreciation | (230,000) | (83,000) |
| Deferred tax liability – Long Term | $(230,000) | $(83,000) |
NOTE 10: EARNINGS PER SHARE
The following table sets forth the computation of basic and diluted earnings per share:
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| Numerator for basic and diluted earnings per share | $1,441,463 | $635,905 |
| Denominator for basic earnings per share - weighted average | 15,743,763 | 15,735,451 |
| Effects of dilutive securities: | ||
| Stock options for employees, directors and outside consultants | 30,244 | 34,048 |
| Denominator for diluted earnings per share | 15,774,007 | 15,769,499 |
| Basic Earnings Per Share – Weighted Average | $0.09 | $0.04 |
| Diluted Earnings Per Share – Weighted Average | $0.09 | $0.04 |
NOTE 11: CUSTOMER CONCENTRATIONS AND FOREIGN SALES
Export sales to customers located outside the United States and Canada were approximately as follows:
| February 29, 2024 | February 28, 2023 | |
|---|---|---|
| Asia Pacific (APAC) | 3,268,000 | 3,260,000 |
| Europe, Middle East, Asia (EMEA) | 4,333,000 | 3,448,000 |
| Latin America | 1,221,000 | 1,546,000 |
| $8,822,000 | $8,254,000 |
During fiscal 2024 and fiscal 2023, sales to foreign customers accounted for approximately $8,822,000 and $8,254,000, or 45% and 55% respectively, of total revenues.
For the fiscal years ended February 29, 2024 and February 28, 2023, no single customer accounted for more than 10% of the Company’s revenues.
Two customers accounted for 26% of the outstanding accounts receivables February 29, 2024.
Two customers accounted for 28% of the outstanding accounts receivables at February 28, 2023.
The Company had two customers which accounted for 14% of sales during fiscal 2023. Four customers accounted for 44% of the outstanding accounts receivables at February 28, 2023.
NOTE 12: COMMITMENTS AND CONTINGENCIES
Other than the letters of credit discussed in Notes 3 and 8, the Company did not have any material commitments or contingencies as of February 29, 2024.
The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition, and cash flows. As of February 29, 2024, the Company did not have any pending legal actions.
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: May 23, 2024
Sono-Tek Corporation
(Registrant)
By:/s/ R. Stephen Harshbarger
R. Stephen Harshbarger,
Chief Executive Officer and President
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| /s/ Dr. Christopher L Coccio | May 23, 2024 | /s/ Eric Haskell | May 23, 2024 |
|---|---|---|---|
| Christopher L. Coccio | Eric Haskell | ||
| Executive Chairman and Chairman of the Board of Directors | Director | ||
| /s/ Stephen J. Bagley | May 23, 2024 | /s/ Dr. Joseph Riemer | May 23, 2024 |
| Stephen J. Bagley | Dr. Joseph Riemer | ||
| Chief Financial Officer | Director | ||
| /s/ Carol O’Donnell | May 23, 2024 | /s/ Philip A. Strasburg | May 23, 2024 |
| Carol O’Donnell | Philip A. Strasburg | ||
| Director | Director | ||
| /s/ R. Stephen Harshbarger | May 23, 2024 | /s/ Dr. Donald F. Mowbray | May 23, 2024 |
| R. Stephen Harshbarger | Donald F. Mowbray | ||
| Chief Executive Officer and President | Director | ||
| /s/ Adeniyi Lawal | May 23, 2024 | ||
| Adeniyi Lawal | |||
| Director | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.